Verification of Therapeutic Effect through Accelerator Mass Spectrometry‐Based Single Cell Level Quantification of hESC‐Endothelial Cells Distributed into an Ischemic Model

Abstract

AbstractAs the potential of pluripotent stem cell‐derived differentiated cells has been demonstrated in regenerative medicine, differentiated vascular endothelial cells (ECs) are emerging as a therapeutic agent for the cardiovascular system. To verify the therapeutic efficacy of differentiated ECs in an ischemic model, human embryonic stem cells (hESCs) are induced as EC lineage and produce high‐purity ECs through fluorescence‐activated cell sorting (FACS). When hESC‐ECs are transplanted into a hindlimb ischemic model, it is confirmed that blood flow and muscle regeneration are further improved by creating new blood vessels together with autologous ECs than the primary cell as cord blood endothelial progenitor cells (CB‐EPCs). In addition, previously reported studies show the detection of transplanted cells engrafted in blood vessels through various tracking methods, but fail to provide accurate quantitative values over time. In this study, it is demonstrated that hESC‐ECs are engrafted approximately sevenfold more than CB‐EPCs by using an accelerator mass spectrometry (AMS)‐based cell tracking technology that can perform quantification at the single cell level. An accurate quantification index is suggested. It has never been reported in in vivo kinetics of hESC‐ECs that can act as therapeutic agents.